SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment
SARS-CoV-2 nasopharyngeal shedding contributes to the spread of the COVID-19 epidemic. Among 3271 COVID-19 patients treated at the Hospital University Institute Méditerranée Infection, Marseille, France from 3 March to 27 April 2020, tested at least twice by qRT-PCR, the median SARS-CoV-2 nasopharyn...
Main Authors: | Michel Drancourt, Sébastien Cortaredona, Cléa Melenotte, Sophie Amrane, Carole Eldin, Bernard La Scola, Philippe Parola, Matthieu Million, Jean-Christophe Lagier, Didier Raoult, Philippe Colson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/5/890 |
Similar Items
-
Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
by: Matthieu MILLION, et al.
Published: (2021-09-01) -
Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19
by: Filippo Albani, et al.
Published: (2020-08-01) -
Hydroxychloroquine and azithromycin use in COVID-19 era and cardiovascular concerns: Current perspective
by: Aditya Kapoor, et al.
Published: (2021-01-01) -
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
by: Samia Arshad, et al.
Published: (2020-08-01) -
The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19
by: Yu. N. Belenkov, et al.
Published: (2020-12-01)